Manager of Commercial Program Management, Freenome
$140.3-216.5k
You will also be eligible to receive pre-IPO equity and cash bonuses
Biological analysis platform for cancer
Open for applications
Biological analysis platform for cancer
201-500 employees
Open for applications
$140.3-216.5k
You will also be eligible to receive pre-IPO equity and cash bonuses
201-500 employees
Company mission
To create tools that empower everyone to prevent, detect, and treat their disease.
Jump to section
Company mission
To create tools that empower everyone to prevent, detect, and treat their disease.
Our take
Freenome is a biotechnology company offering a biological analysis platform that uses molecular biology and machine learning to detect cancer with a routine blood draw. The platform trains on thousands of cancer-positive blood samples to recognise disease-associated patterns and help detect early-stage cancer, allowing clinicians to optimise treatments.
The company specialises in advanced computational biology, using machine learning to detect patterns among billions of circulating cell-free biomarkers. Freenome continues to focus on the development of its colorectal cancer test, potentially helping the 45 million people not currently up-to-date on colorectal cancer screening guidelines in the United States.
Following its 2022 funding round, the company surpassed the $1 billion funding mark. Freenome is set to accelerate the development of its platform, testing for additional cancers and furthering its blood test detection technology. It's also forming partnerships for R&D purposes, joining forces with health firms such as Geisinger to provide real-world data that could help it detect multiple cancers.
Steph
Company Specialist at Welcome to the Jungle
Company values
- Strive for Greatness: We choose to take on cancer not because it's easy, but because it's hard
- Servant Leadership: We lead by example and help others grow to their full potential
- Trust: We recognize trust is built over time and value long-term relationships, not short-term transactions
- Integrity: We courageously do what is right, and are fact-based, data-driven, and accountable for results
- Empathy: We seek to understand before being understood and build products that equitably serve diverse communities
Funding (last 2 of 7 rounds)
Feb 2024
$254m
LATE VC
Dec 2021
$300m
SERIES D
Total funding: $1.1bn
This company has top investors
Leadership
Riley Ennis
(Co-Founder & PO)Studied at Yale, Johns Hopkins and Dartmouth. Was a Thiel Fellow and co-founded Immudicon and Oncolinx.
Articles
Jobs (5)
Software Engineering
Marketing
Operations & Strategy